Angiogenesis in cancer

被引:1041
作者
Nishida, Naoyo [1 ,2 ,3 ]
Yano, Hirohisa [1 ]
Nishida, Takashi [4 ]
Kamura, Toshiharu [2 ,3 ]
Kojiro, Masamichi [1 ]
机构
[1] Kurume Univ, Sch Med, Dept Pathol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan
[2] Kurume Univ, Sch Med, Dept Obstet & Gynecol, Kurume, Fukuoka, Japan
[3] Kurume Univ, Sch Med, Res Ctr Innovat Canc Therapy 21 Century, COE Program Med Sci, Kurume, Fukuoka, Japan
[4] Hita Saiseikai Hosp, Oita, Japan
关键词
angiogenesis; immunohistochemistry; prognosis;
D O I
10.2147/vhrm.2006.2.3.213
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
New growth in the vascular network is important since the proliferation, as well as metastatic spread, of cancer cells depends on an adequate supply of oxygen and nutrients and the removal of waste products. New blood and lymphatic vessels form through processes called angiogenesis and lymphangiogenesis, respectively. Angiogenesis is regulated by both activator and inhibitor molecules. More than a dozen different proteins have been identified as angiogenic activators and inhibitors. Levels of expression of angiogenic factors reflect the aggressiveness of tumor cells. The discovery of angiogenic inhibitors should help to reduce both morbidity and mortality from carcinomas. Thousands of patients have received antiangiogenic therapy to date. Despite their theoretical efficacy, antiangiogeic treatments have not proved beneficial in terms of long-term survival. There is an urgent need for a new comprehensive treatment strategy combining antiangiogenic agents with conventional cytoreductive treatments in the control of cancer.
引用
收藏
页码:213 / 219
页数:7
相关论文
共 99 条
  • [1] Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
    Achen, MG
    Jeltsch, M
    Kukk, E
    Mäkinen, T
    Vitali, A
    Wilks, AF
    Alitalo, K
    Stacker, SA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) : 548 - 553
  • [2] Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa
    Amioka, T
    Kitadai, Y
    Tanaka, S
    Haruma, K
    Yoshihara, M
    Yasui, W
    Chayama, K
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (10) : 1413 - 1419
  • [3] Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO
  • [4] 2-5
  • [5] An integrated approach for tailored treatment in breast cancer
    Awada, A
    de Castro, G
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 203 - 208
  • [6] The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man
    Baldwin, ME
    Catimel, B
    Nice, EC
    Roufail, S
    Hall, NE
    Stenvers, KL
    Karkkainen, MJ
    Alitalo, K
    Stacker, SA
    Achen, MG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (22) : 19166 - 19171
  • [7] Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia
    Bellomo, D
    Headrick, JP
    Silins, GU
    Paterson, CA
    Thomas, PS
    Gartside, M
    Mould, A
    Cahill, MM
    Tonks, ID
    Grimmond, SM
    Townson, S
    Wells, C
    Little, M
    Cummings, MC
    Hayward, NK
    Kay, GF
    [J]. CIRCULATION RESEARCH, 2000, 86 (02) : E29 - E35
  • [8] Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
    Boehm, T
    Folkman, J
    Browder, T
    OReilly, MS
    [J]. NATURE, 1997, 390 (6658) : 404 - 407
  • [9] EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ITS RECEPTORS FLT AND KDR IN OVARIAN-CARCINOMA
    BOOCOCK, CA
    CHARNOCKJONES, DS
    SHARKEY, AM
    MCLAREN, J
    BARKER, PJ
    WRIGHT, KA
    TWENTYMAN, PR
    SMITH, SK
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (07): : 506 - 516
  • [10] Cancer - Out of air is not out of action
    Bottaro, DP
    Liotta, LA
    [J]. NATURE, 2003, 423 (6940) : 593 - 595